Remote Ischemic Postconditioning Enhances Ketone Body-Mediated Ferroptosis Inhibition in Stroke Models

Study Background and Research Question

Ischemic stroke, a leading cause of death and long-term disability, results primarily from cerebral blood flow interruption and subsequent reperfusion injury. Despite advances in acute interventions such as thrombolysis and mechanical thrombectomy, effective neuroprotective strategies for poststroke care remain limited. Remote ischemic postconditioning (RIPostC)—the application of brief, non-lethal ischemia to a limb or distant organ after a stroke—has shown promise in reducing tissue damage, but its molecular mechanisms are incompletely understood. This study sought to delineate whether RIPostC-induced neuroprotection involves modulation of energy metabolism and, specifically, if it leverages endogenous ketone body signaling to inhibit ferroptosis, a regulated form of iron-dependent cell death implicated in neuronal loss after stroke (reference study).

Key Innovation from the Reference Study

The central innovation of this research lies in demonstrating that RIPostC's neuroprotective effects are mediated, at least in part, by upregulation of ketone body production—most notably 3-hydroxybutyrate (BHBA)—and its subsequent inhibition of ferroptosis in neuronal tissue. This mechanistic link positions ketone body signaling as a critical target for poststroke intervention strategies and clarifies the role of metabolic shifts in modulating cell death pathways following ischemic injury.

Methods and Experimental Design Insights

The investigators employed a well-characterized rat model of middle cerebral artery occlusion (MCAO) to induce focal cerebral ischemia, followed by reperfusion. RIPostC was administered as a sequence of transient hindlimb ischemia episodes immediately after the onset of reperfusion. Neurological outcomes were assessed using motor function tests, infarct volume quantification, and apoptosis assays (TUNEL staining). To probe metabolic and ferroptotic changes, the study measured ATP and lactate levels, ketone body concentrations in brain tissue, markers of lipid peroxidation, glutathione peroxidase 4 (GPX4) and acyl-CoA synthetase long-chain family member 4 (ACSL4) protein expression, and iron content. In vitro, HT22 hippocampal neurons were exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) with or without exogenous ketone bodies, with erastin used as a ferroptosis inducer to clarify pathway specificity.

Protocol Parameters

• RIPostC protocol: Applied as three cycles of 10-min hindlimb ischemia followed by 10-min reperfusion, initiated at the onset of cerebral reperfusion in MCAO rats.
• Ketone body supplementation (in vitro): BHBA and other ketone bodies were added at concentrations mimicking physiological ketosis (typically 1–5 mM), as supported by both this study and internal guidance.
• Ferroptosis induction: Erastin applied to cell cultures to confirm the role of ferroptosis in neuronal death and the protective effect of ketone bodies.

Core Findings and Why They Matter

RIPostC significantly reduced infarct volume, mitigated neurological deficits, and decreased neuronal apoptosis in rats subjected to MCAO. Metabolic profiling revealed that RIPostC enhanced ATP production, decreased lactate accumulation, and increased cerebral levels of ketone bodies, including BHBA. Importantly, RIPostC reversed markers of ferroptosis: it maintained GPX4 expression, suppressed ACSL4, limited lipid peroxidation, and reduced both total and ferrous iron content by downregulating iron transporters.

In vitro, exogenous ketone bodies preserved GPX4 and mitochondrial structure in OGD/R-treated neurons and suppressed ACSL4, but these effects were abolished by erastin, supporting a causal link between ketone body signaling and ferroptosis inhibition. Collectively, these findings identify BHBA and related metabolites as neuroprotective agents acting through a ferroptosis-suppression mechanism, with RIPostC as a physiological trigger for this pathway (reference study).

Comparison with Existing Internal Articles

Previous reviews and mechanistic studies have highlighted the dual role of 3-hydroxybutyrate as both a fatty acid β-oxidation metabolite and a signaling molecule with epigenetic modulatory properties. For example, recent overviews describe BHBA as a class I histone deacetylase inhibitor, linking cellular metabolic state with chromatin regulation and gene expression (internal article). The current reference study adds a crucial in vivo dimension by connecting RIPostC-induced endogenous BHBA production with inhibition of ferroptosis—a mechanism not previously demonstrated in this context. While internal resources discuss BHBA’s application in cell-based neuroprotection assays (protocol-focused article), this study provides direct experimental evidence of its role in mediating neuroprotection through metabolic and iron regulation pathways, rather than solely via chromatin remodeling.

Limitations and Transferability

While the findings robustly support a neuroprotective role for RIPostC-driven ketone body elevation and ferroptosis inhibition, several limitations are notable. The study is based on rodent models, and the translational relevance to human stroke patients remains to be established. The precise contribution of individual ketone bodies versus other metabolic changes induced by RIPostC requires further dissection. Additionally, the interplay between ferroptosis and other cell death modalities (such as apoptosis and necroptosis) in the context of metabolic reprogramming warrants deeper investigation. Finally, while the in vitro data provide mechanistic support, they do not fully capture the complexity of the in vivo neurovascular environment.

Research Support Resources

Researchers interested in replicating or extending these findings can utilize 3-hydroxybutyrate (BHBA, SKU M1297) as a validated ketone body signaling molecule for in vitro and in vivo modeling. According to the product information, BHBA is suitable for simulating physiological and pathophysiological ketosis, supporting studies on metabolic neuroprotection, ferroptosis regulation, and epigenetic modulation. For workflow guidance, protocol recommendations from internal resources are available (cell-based assay guidance). BHBA from APExBIO offers a reliable option for researchers targeting the intersection of metabolic and cell death pathways in neuroprotection studies.